The Development of iManage-PC, an Online Symptom Monitoring and Self-management Tool for Men With Clinically Localized Prostate Cancer.
Karly M Murphy, Christina Sauer, Dershung Yang and 6 others
PMID 33867430WHAT IT FOUND
Men with localized prostate cancer used an online symptom-monitoring and self-management tool for four weeks with high adherence and satisfaction.
They reported better confidence and some urinary and bowel symptom improvements, but prostate cancer anxiety did not improve.
Key findings
0189 of 96 men completed follow-up measures, and 94.3% rated the tool quite or very easy to use.
02Bowel symptoms, urinary symptoms, and anxiety decreased significantly over the intervention period, while erectile function and sexual satisfaction did not change significantly.
03Participants reported increased self-efficacy and better global physical and mental health after the intervention, but prostate cancer related anxiety did not improve significantly.
STILL TO COME
How it was doneWhat they foundWhat it means for PTsWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The pilot was single arm and not designed to test efficacy, so pre-post changes cannot be attributed to iManage-PC. The sample was mainly highly educated, Caucasian men, which limits generalizability. Intervention content was not formally evaluated for cultural relevance. Only 57.6% of participants watched at least one video, so results may not reflect full engagement with the self-management content. 92 participants had baseline and follow-up outcome data, while 89 of 96 completed follow-up measures, so analysed numbers differ. The follow-up period was only 4 weeks.
The easy way to misread this
Do not conclude that iManage-PC caused the symptom improvements. This was a single-arm pilot with no control group, and the authors state that pre-post changes may have been influenced by other factors.